Stock Track | Ironwood Pharmaceuticals Surges 5% on Robust LINZESS Growth and Pipeline Progress

Stock Track

Nov 08, 2024

Ironwood Pharmaceuticals Inc. (IRWD) saw its stock soar by 5.15% on Thursday, November 8th, following the release of its third-quarter 2024 financial results. The surge in share price can be attributed to the company's continued growth in its flagship product LINZESS and the positive developments in its drug pipeline.

Although Ironwood missed analysts' earnings estimates, reporting earnings per share of $0.02 versus the expected $0.08, the company's revenue of $91.59 million slightly exceeded expectations of $91.25 million. The strong performance was driven by LINZESS, which saw a 13% year-over-year increase in prescription demand growth during the third quarter.

Despite facing pricing headwinds, Ironwood remains optimistic about the future of LINZESS. The company is actively exploring strategies, such as copay assistance and over-the-counter opportunities, to maximize the drug's profitability and cash flow as it approaches the loss of exclusivity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1149299100"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1149299100\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1149299100?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-08 22:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1149299100","market":"hk","top_or_hot":-1,"title":"Stock Track | Ironwood Pharmaceuticals Surges 5% on Robust LINZESS Growth and Pipeline Progress","media":"Stock Track","content":"<p>Ironwood Pharmaceuticals Inc. (IRWD) saw its stock soar by 5.15% on Thursday, November 8th, following the release of its third-quarter 2024 financial results. The surge in share price can be attributed to the company's continued growth in its flagship product LINZESS and the positive developments in its drug pipeline.</p>\n\n<p>Although Ironwood missed analysts' earnings estimates, reporting earnings per share of $0.02 versus the expected $0.08, the company's revenue of $91.59 million slightly exceeded expectations of $91.25 million. The strong performance was driven by LINZESS, which saw a 13% year-over-year increase in prescription demand growth during the third quarter.</p>\n\n<p>Despite facing pricing headwinds, Ironwood remains optimistic about the future of LINZESS. The company is actively exploring strategies, such as copay assistance and over-the-counter opportunities, to maximize the drug's profitability and cash flow as it approaches the loss of exclusivity.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Ironwood Pharmaceuticals Surges 5% on Robust LINZESS Growth and Pipeline Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Ironwood Pharmaceuticals Surges 5% on Robust LINZESS Growth and Pipeline Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-11-08 22:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ironwood Pharmaceuticals Inc. (IRWD) saw its stock soar by 5.15% on Thursday, November 8th, following the release of its third-quarter 2024 financial results. The surge in share price can be attributed to the company's continued growth in its flagship product LINZESS and the positive developments in its drug pipeline.</p>\n\n<p>Although Ironwood missed analysts' earnings estimates, reporting earnings per share of $0.02 versus the expected $0.08, the company's revenue of $91.59 million slightly exceeded expectations of $91.25 million. The strong performance was driven by LINZESS, which saw a 13% year-over-year increase in prescription demand growth during the third quarter.</p>\n\n<p>Despite facing pricing headwinds, Ironwood remains optimistic about the future of LINZESS. The company is actively exploring strategies, such as copay assistance and over-the-counter opportunities, to maximize the drug's profitability and cash flow as it approaches the loss of exclusivity.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IRWD","symbol_name":"Ironwood医药","start_time":0,"source_url":"","article_id":"1149299100","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1149299100","pubTimestamp":1731077955,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Ironwood Pharmaceuticals Inc.  saw its stock soar by 5.15% on Thursday, November 8th, following the release of its third-quarter 2024 financial results. The surge in share price can be attributed to the company's continued growth in its flagship product LINZESS and the positive developments in its drug pipeline.Although Ironwood missed analysts' earnings estimates, reporting earnings per share of $0.02 versus the expected $0.08, the company's revenue of $91.59 million slightly exceeded expectati","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IRWD":"Ironwood医药"},"translate_title":"股票轨迹Ironwood Pharmaceuticals因LINZESS强劲增长和管道进展而飙升5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IRWD":1},"content_text":"Ironwood Pharmaceuticals Inc. (IRWD) saw its stock soar by 5.15% on Thursday, November 8th, following the release of its third-quarter 2024 financial results. The surge in share price can be attributed to the company's continued growth in its flagship product LINZESS and the positive developments in its drug pipeline.\nAlthough Ironwood missed analysts' earnings estimates, reporting earnings per share of $0.02 versus the expected $0.08, the company's revenue of $91.59 million slightly exceeded expectations of $91.25 million. The strong performance was driven by LINZESS, which saw a 13% year-over-year increase in prescription demand growth during the third quarter.\nDespite facing pricing headwinds, Ironwood remains optimistic about the future of LINZESS. The company is actively exploring strategies, such as copay assistance and over-the-counter opportunities, to maximize the drug's profitability and cash flow as it approaches the loss of exclusivity.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}